274 related articles for article (PubMed ID: 33454385)
21. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
[TBL] [Abstract][Full Text] [Related]
22. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.
Huang R; Shen YW; Guan YY; Jiang YX; Wu Y; Rahman K; Zhang LJ; Liu HJ; Luan X
Acta Biomater; 2020 Oct; 116():1-15. PubMed ID: 32911102
[TBL] [Abstract][Full Text] [Related]
23. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges.
Rosenholm JM; Sahlgren C; Lindén M
Nanoscale; 2010 Oct; 2(10):1870-83. PubMed ID: 20730166
[TBL] [Abstract][Full Text] [Related]
24. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
25. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
[TBL] [Abstract][Full Text] [Related]
26. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
27. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
28. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
29. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles.
Chen Y; Chen H; Shi J
Adv Mater; 2013 Jun; 25(23):3144-76. PubMed ID: 23681931
[TBL] [Abstract][Full Text] [Related]
30. How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature.
Porrang S; Davaran S; Rahemi N; Allahyari S; Mostafavi E
Int J Nanomedicine; 2022; 17():1803-1827. PubMed ID: 35498391
[TBL] [Abstract][Full Text] [Related]
31. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
32. Hybrid mesoporous silica nanospheres modified by poly (NIPAM-co-AA) for drug delivery.
Zhang K; Zhou D; Wang Z; Zhang Y; He P
Nanotechnology; 2019 Aug; 30(35):355604. PubMed ID: 31071691
[TBL] [Abstract][Full Text] [Related]
33. Impact of macroporous silica nanoparticles at sub-50nm on bio-behaviors and biosafety in drug-resistant cancer models.
Xu W; Zhou M; Guo Z; Lin S; Li M; Kang Q; Xu Y; Zhang X; Xie J
Colloids Surf B Biointerfaces; 2021 Oct; 206():111912. PubMed ID: 34147925
[TBL] [Abstract][Full Text] [Related]
34. The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles.
Chowdhury MA
Curr Drug Deliv; 2016; 13(6):839-56. PubMed ID: 26638978
[TBL] [Abstract][Full Text] [Related]
35. Molecular Elucidation of Biological Response to Mesoporous Silica Nanoparticles in Vitro and in Vivo.
Chou CC; Chen W; Hung Y; Mou CY
ACS Appl Mater Interfaces; 2017 Jul; 9(27):22235-22251. PubMed ID: 28608695
[TBL] [Abstract][Full Text] [Related]
36. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
37. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
38. Advances in Peptide Functionalization on Mesoporous Silica Nanoparticles for Controlled Drug Release.
Hu JJ; Xiao D; Zhang XZ
Small; 2016 Jul; 12(25):3344-59. PubMed ID: 27152737
[TBL] [Abstract][Full Text] [Related]
39. Mesoporous Silica Nanoparticles with Large Pores for the Encapsulation and Release of Proteins.
Tu J; Boyle AL; Friedrich H; Bomans PH; Bussmann J; Sommerdijk NA; Jiskoot W; Kros A
ACS Appl Mater Interfaces; 2016 Nov; 8(47):32211-32219. PubMed ID: 27933855
[TBL] [Abstract][Full Text] [Related]
40. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
